恩格列净降低慢性肾脏病患者血清尿酸:EMPA-KIDNEY试验探索性分析
EMPA-KIDNEY试验随机6609例CKD患者接受恩格列净10mg/日或安慰剂,中位随访2年。恩格列净组血清尿酸平均组间差异为-25.6 µmol/l(95%CI -30.3至-21.0),但未显著减少痛风事件。
要点
- 恩格列净使CKD患者血清尿酸平均降低25.6 µmol/l。
- 降尿酸幅度在eGFR较高和无糖尿病患者中更大。
- 尿酸降低未转化为痛风事件风险的显著下降。
核心结论
- SGLT2抑制降低CKD患者血清尿酸,但幅度不大且未减少痛风风险。
研究设计与样本
- EMPA-KIDNEY随机对照试验,6609例CKD患者随机接受恩格列净10mg/日或安慰剂,中位随访2年。
主要发现
- 基线平均血清尿酸为431±114 µmol/l。
- 恩格列净组血清尿酸平均组间差异为-25.6 µmol/l(95%CI -30.3至-21.0)。
- 恩格列净未显著减少首次痛风事件(HR 0.87,95%CI 0.74-1.02,595例首次事件)或总痛风事件(HR 0.86,95%CI 0.72-1.03,869例总事件)。
- 恩格列净对主要结局和肾脏病进展结局的影响与基线尿酸水平无关。
临床怎么用
- 恩格列净可用于降低CKD患者尿酸,但不应作为降尿酸治疗的主要手段。
- 不应期望通过恩格列净显著减少痛风发作。
局限性
- 痛风事件为参与者报告,可能存在漏报或误分类。
- 探索性分析,痛风相关结局并非主要终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD. METHODS: The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg daily or matching placebo over a median of 2 years of follow-up. Serum uric acid was measured at randomisation then at 2 and 18 months of follow-up and the effects of empagliflozin were analysed using a pre-specified mixed model repeated measures approach. Participant-reported gout events were analysed in Cox regression models (first events) with the Andersen-Gill extension (total events). A post hoc composite outcome included new initiation of uric acid-lowering therapy or colchicine. EMPA-KIDNEY primary and kidney disease progression outcomes were also assessed in subgroups of baseline serum uric acid. RESULTS: Baseline mean ± standard deviation serum uric acid concentration was 431 ± 114 µmol/l. Allocation to empagliflozin resulted in a study-average between-group difference in serum uric acid of -25.6 µmol/l [95% confidence interval (CI) -30.3 to -21.0], with larger effects in those with higher eGFR (trend P < .001) and without diabetes (heterogeneity P < .001). Compared with placebo, empagliflozin did not significantly reduce first or total gout events [hazard ratio 0.87 (95% CI 0.74-1.02) for the 595 first events and 0.86 (0.72-1.03) for the 869 total events] with similar hazard ratios for the post hoc composite and across subgroups, including by diabetes and eGFR. The effect of empagliflozin on the primary outcome and kidney disease progression outcomes were similar irrespective of the baseline level of uric acid. CONCLUSIONS: SGLT2 inhibition reduces serum uric acid in patients with CKD, with larger effects at higher eGFR and in the absence of diabetes. However, the effect on uric acid is modest and did not translate into reduced risk of gout in EMPA-KIDNEY.
引用
- Mayne KJ, Sardell RJ, Staplin N, et al. Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2025. PMID: 39277784. doi:10.1093/ndt/gfae203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。